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Abstract
Background: The Innate immune system constitutes the first line of defense against pathogen infections. The Retinoic acid-
inducible gene I (RIG-I) receptor recognizes triphosphorylated ssRNAs and dsRNA to initiate downstream signaling of
interferon response. However, unregulated activity of these receptors could lead to autoimmune diseases. We seek to
identify small molecules that can specifically regulate RIG-I signaling.
Methodology/Principal Findings: Epigallocatechin gallate (EGCG), a polyphenolic catechin present in green tea, was
identified in a small molecule screen. It was found to bind RIG-I and inhibits its signaling at low micromolar concentrations
in HEK293T cells. Furthermore, EGCG dose-dependently inhibited the ATPase activity of recombinant RIG-I but did not
compete with RIG-I interaction with RNA or with ATP. EGCG did not inhibit signaling by Toll-like receptors 3, 4, 9 or
constitutive signaling by the adapter protein IPS-1. Structure activity relationship analysis showed that EGCG, its epimer
GCG and a digallate-containing compound, theaflavin 3,39 digallate (TFDG) were potent RIG-I inhibitors. EGCG also inhibited
IL6 secretion and IFN- b mRNA synthesis in BEAS-2B cells, which harbors intact endogenous RIG-I signaling pathway.
Conclusions/Significance: EGCG and its derivatives could have potential therapeutic use as a modulator of RIG-I mediated
immune responses.
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Introduction
Multiple, at least partially overlapping, pathways are used to
detect viral infections [1]. During RNA virus infection, double-
stranded RNAs (dsRNA) and uncapped transcripts generated
during replication can serve as pathogen-associated molecular
patterns recognized by innate immune receptors [1,2]. Agonist
binding by these receptors results in changes in signal transduction
that can lead to establishment of antiviral responses as well as
mediate adaptive immune responses. Improper regulation of
signaling by these receptors could result in inflammation-
associated pathologies. It is therefore important to be able to
modulate the signal transduction by the innate immune receptors.
The Retinoic acid inducible gene I (RIG-I) encodes a receptor
that recognizes cytoplasmic RNAs. The RIG-I protein contains
two N-terminal caspase recruitment domains (CARD), a central
DExD/H RNA helicase domain, and a C-terminal regulatory
domain of 190 amino acids that interacts with the helicase domain
and the CARD domain to suppress signaling [3]. Upon agonist
binding by the regulatory and possibly the helicase domains, RIG-
I undergoes a conformational change to expose the CARD
domain and may also cause multimerization of RIG-I [3]. The
exposed CARDs can then interact with and activate its adaptor
protein IPS-1 (also known as MAVS, VISA and Cardif), a
mitochondrial membrane protein, to activate signal transduction
through the transcription factors IRF3 and NF-kB resulting in
increases in cytokine production [4,5].
Regulation of RIG-I signaling has been an area of intense focus
in part because it can modulate the outcome of virus infection and
also inflammation-associated diseases. Several types of ligands are
recognized by RIG-I. Single- and double-stranded RNAs with a 59
terminal triphosphate are specifically recognized by C-terminal
regulatory domain [6–10]. This recognition could serve to
discriminate between self (capped mRNAs) and nonself RNAs
(that may not be capped). Highly structured portions within the
hepatitis C virus (HCV) genomic RNA and the polyuridine motif
of the 39 untranslated region are also ligands for RIG-I [3,11,12].
RIG-I could also recognize blunt-ended dsRNA that lack a 59
triphosphate due to the stacking of a phenylalanine in the C-
terminal regulatory domain with the terminal base pair of the
RNA [13,14]; unpublished data]. Single-stranded DNAs contain-
ing phosphorothioates are also potent antagonists of RIG-I
activation of signal transduction [13].
We seek to identify chemical modulators of RIG-I for use as
tools to elucidate RIG-I’s mechanism of action. A screen of a small
molecule chemical library revealed that the Epigallocatechin-3-
gallate (EGCG) could bind to RIG-I and modulate its signaling.
EGCG is one of the four major polyphenolic catechins that are
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12878found in green tea. These catechins have been linked to important
health benefits including reduced risk for atherosclerosis, cancer,
oxidative damage from free radicals and cardiovascular diseases
[15–17]. EGCG inhibited RIG-I signaling in a cell-based reporter
assay and RNA-dependent ATPase activity of recombinant RIG-I
protein in biochemical assays. In lung epithelial BEAS-2B cells,
EGCG inhibited RIG-I-specific IL-6 production. The inhibitory
effect of EGCG was also observed with MDA-5, but not observed
with several Toll-like receptors. To our knowledge EGCG is the
first natural small molecule to regulate RIG-I dependent signal
transduction.
Results
EGCG inhibits RIG-I signaling
We used a cell-based RIG-I dependent luciferase reporter assay
to identify modulators of RIG-I signaling. The RNA agonist used
to induce RIG-I signaling was a single-stranded RNA with a 59
triphosphate named shR9. A screen of ,2000 compounds, from
the NIH Clinical Collection (NCC), and commercial chemical
libraries, tested at 10 mM yielded 75 potential activators or
inhibitors of shR9-dependent RIG-I signal transduction (Figure
S1A). To determine whether these compounds acted directly on
RIG-I, or affected the signaling cascade downstream of RIG-I, we
measured their effects on shR9 dependent RIG-I ATPase activity
in a biochemical assay. Recombinant RIG-I exhibits ATPase
activity only in the presence of agonists [13]. None of the putative
activators of RIG-I signaling increased RIG-I ATPase activity in
the absence or presence of RNA agonist. However, one inhibitor,
EGCG, reduced shR9-dependent RIG-I ATPase activity (Figure
S1B) and was chosen for further characterization.
EGCG inhibited shR9-dependent RIG-I signaling in a
concentration-dependent manner, with an IC50 between 1 to
2 mM in the cell-based reporter assay (Figure 1A). EGCG reduced
RIG-I signaling at all concentrations of the transfected RIG-I
plasmid tested (Figure 1B). Similar IC50 values were found with
blunt ended dsRNA ligand of 27 bp (dsR27) and the heteroge-
neous poly(I:C) (Figure 1C). In addition, similar results were
obtained when the NF-kB-Luc and ISRE-Luc reporters were used
instead of the IFN-b-luc reporter (Table 1).
EGCG inhibited ATPase activity induced by shR9 in vitro in a
concentration-dependent manner, with an IC50 less than 0.5 mM
(Figure 1D). Increasing the concentration of recombinant RIG-I
protein in the presence of constant amount of EGCG and shR9
reduced the inhibitory effect of EGCG, likely by titrating away
EGCG (Figure S1C). These results suggest that EGCG acts by
binding to RIG-I or the RIG-I-agonist complex.
To validate EGCG as a RIG-I inhibitor that warrants further
characterizations, its cytotoxicity was tested using the WST-1 assay
that assesses for mitochondrial succinate-tetrazolium reductase in
viable cells. EGCG had no significant affect on cell viability at
concentration up to 10 mM, more than 10-fold of IC50 (Figure 1D
Figure 1. EGCG inhibits RIG-I signaling. (A) Effect of EGCG titration on triphosphorylated ssRNA, shR9-dependent RIG-I signaling. EGCG was
added to HEK293T cells expressing full length RIG-I, IFN-b luciferase and Renilla luciferase reporters as described in the methods. The presence
(+ shR9) and absence (- shR9) of shRNA shows the background and induced level of reporter expression in the presence of RIG-I. The activation of
signaling obtained upon transfection of shR9 in the absence of EGCG was set as 100%. The chemical structure of EGCG is shown in the inset. The data
are shown as a mean +/2 standard deviation. (B) Effect of RIG-I plasmid concentration on EGCG inhibition. HEK293T cells were transfected with
increasing amounts of pUNORIG-I plasmid that expresses full length RIG-I without changing the amount of reporter plasmids. The total amount of
plasmids was kept constant by addition of pUNO vector plasmid. EGCG was added at 2 mM and DMSO was used as control. The data are represented
as a mean +/2 standard deviation. (C) Activation of RIG-I signaling with single and double stranded RNA agonists was inhibited by EGCG in the
reporter assay in HEK293T cells. The data are shown as a mean +/2 standard deviation. (D) EGCG inhibits ATPase activity of recombinant full length
RIG-I. Different amounts of EGCG were added along with shR9 agonist to the ATPase reaction. ATPase activity obtained with DMSO was considered as
100%. (E) WST-1 assay to determine the toxicity of EGCG in HEK293T cells. The data are shown as a mean +/2 standard deviation.
doi:10.1371/journal.pone.0012878.g001
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based reporter assays was also unaffected by up to 10 mMo f
EGCG (data not shown). EGCG thus has minimal cytotoxicity at
the concentrations capable of inhibiting signal transduction by
RIG-I.
Specificity of EGCG on RIG-I
To test whether EGCG has specificity for RIG-I, we used luciferase
reporter assays drivenby NF-kB promoter elements that are responsive
to TLR3, TLR4, TLR9 as well as RIG-I. At 2 mM, EGCG did not
affect signaling by TLR3, TLR4 or TLR9, demonstrating a selective
effect for RIG-I among the receptors tested (Table 1).
To confirm the specificity of EGCG, we expressed the RIG-I
adaptor, IPS-1, from a strong promoter, which will activate ligand-
independent signal transduction [18]. EGCG was unable to inhibit
ligand-independent IPS-1-activated reporters, demonstrating that
EGCG did not affect the signaling pathway downstream of IPS-1
activation (Table 1). Finally, another anti-inflammatory com-
pound, Clemizole, did not significantly affect signaling by any of
the receptors tested, including RIG-I. EGCG did inhibit MDA5
with an IC50 between 1 to 2 mM, similar to the IC50 of RIG-I
(Figure S2). These results demonstrate that EGCG can specifically
affect RIG-I-like receptors (Table 1).
Effects of EGCG on ATP binding by RIG-I
Shim et al. [19] reported that EGCG binds to ZAP-70 kinase at
the catalytic site and blocks the ATP-binding pocket, prompting us
to examine whether EGCG could have a similar effect on RIG-I.
Increasing ATP concentration up to 2 mM resulted in a
corresponding increase in RIG-I ATPase activity (Figure 2A).
However, 1 mM of EGCG inhibited the ATPase activity of RIG-I
to 30% in the presence of 2 mM ATP, suggesting that EGCG does
not interfere with ATP binding site or acts on portions of RIG-I in
addition to the ATP binding site. To confirm this, we tested RIG-I
with a Walker A box mutation (K270A) that affected signaling by
RIG-I in response to triphosphorylated ssRNA, but not to
poly(I:C) [13]. EGCG inhibited poly(I:C)-dependent signaling of
RIG-I K270A mutant to the same level as the wild type
(Figure 2B). This result further supports our claim that EGCG is
not acting as a competitive inhibitor of ATP-binding by RIG-I.
EGCG and RNA-binding by RIG-I
We next examined whether EGCG could affect RNA binding
by RIG-I. Should EGCG and the ligand compete for the same
binding pocket, increasing the RNA concentration would affect
the kinetics of EGCG inhibition. SsRNA and dsRNA were
transfected into HEK293T cells expressing RIG-I at concentra-
tions from 10 nM to 1 mM and approximately 100 nM of the
triphosphorylated shR9 saturated RIG-I signaling (Figure 3A).
EGCG at 2 mM reduced RIG-I signaling induced by 10 nM
RNA. Notably, a ten-fold higher shR9 was unable to reverse the
inhibitory effect of EGCG, indicating that EGCG is not a
competitive inhibitor of the RIG-I recognition of triphosphory-
lated RNA (Figure 3A). Similar results were obtained with dsR27
and poly(I:C) (Figure 3B & 3C).
Several mutations in the RIG-I regulatory domain that affected
RNA binding have been characterized [6,7,14]. Mutants, H847A,
K858A, and K861A all exhibited varying degrees of reduced RIG-
I-dependent signal transduction (Figure S3). However, EGCG at
2 mM was able to further reduce reporter activation by all of three
mutants (Figure S3).
The ATPase assay was used to examine whether RNA and
EGCG have distinct binding requirements. Triphosphorylated
ssRNA and dsRNA were added to the assay while EGCG and
protein concentrations were kept constant (Figure 3D–F). Both
shR9 and dsR27 at 10 mM and poly(I:C) at 10 mg were unable to
overcome the inhibition by 1 mM of EGCG. All the results from
Figure 3 and Figure S3 suggest that if EGCG is competing for
RNA binding to RIG-I, it has a higher affinity than the RNA.
Effects of EGCG on RIG-I deletion mutants
To test potential interaction site of EGCGin RIG-I, we tested RIG-
I deletion mutants that can activate signal transduction in the absence
of exogenous ligands. The deletion mutant R-C harbors the two
CARD domains (N terminal 228 a.a.) while the R-CH mutant
contains the CARD and the helicase domains (N-terminal 734 aa).
Both mutants exhibit ligand-independent signal transduction
(Figure 4A). Not surprisingly, transfection of shR9 did not significantly
induce signaling by R-C and R-CH. EGCG did not inhibit
constitutive signaling of R-C and R-CH, suggesting that it does not
interact with the CARD domain or the helicase domain (Figure 4A).
A RIG-I double mutant R-TS/A (T409A/S411A) also
exhibited enhanced ligand-independent activity when compared
to wild-type RIG-I [13] (Figure 4B). R-TS/A retained the ability
to respond to agonists, whose presence resulted in an elevated
reporter expression. EGCG inhibited shR9-dependent signaling of
R-TS/A similar to the level of WT RIG-I but did not significantly
affect ligand-independent constitutive signaling (Figure 4B). Taken
together with the results from the analysis of effects with the
ligand-binding pocket and the ATPase pocket, we concluded that
EGCG could act on the ligand-bound complex of RIG-I.
To further confirm this hypothesis, we assessed the effects of the
time of EGCG addition on shR9–dependent RIG-I ATPase
activity. RIG-I was incubated with EGCG and RNA together, or
with EGCG 10 minutes before or after RNA, prior to ATP
addition (Figure 4C). Similar levels of inhibition were observed
when EGCG was added with, before, or after, the RNA. These
results show that EGCG could inhibit RIG-I after RNA binding,
Table 1. Specificity of EGCG inhibition.
% Activity
RIG-I TLR3 TLR4 TLR9 IPS-1
IFN-b NF-kB ISRE ISRE NF-kB NF-kB NF-kB NF-kB
EGCG (2 mM) 41 (1) 42 (2) 40 (1) 87 (7) 90 (5) 110 (8) 91 (12) 97 (8)
Clemizole (2 mM) 119 (5) 147 (17) 121 (26) 128 (17) 99 (2) 97 (11) 98 (5) 111 (6)
The % activity is the normalized signaling activity by the innate immune receptor or the adaptor IPS-1 observed in the presence of 2 mM of EGCG and Clemizole in the
reporter assay using HEK293T cells. The numbers correspond to the mean of the experiment and the standard deviation is in parenthesis. Analysis was performed using
firefly luciferase reporter driven by IFN-b,N F - kB or ISRE promoters as mentioned above the % activity.
doi:10.1371/journal.pone.0012878.t001
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after EGCG binding. In the cell-based reporter assay, EGCG
added together with transfected shR9, or 5 h prior to RNA
transfection, resulted in a similar degree of inhibition (Figure 4D).
However, EGCG added 1 or 5 h after shR9 failed to inhibit RIG-I
(Figure 4D and 4E). This result is expected in the cell-based assays,
since signaling should be rapid after the agonist-bound RIG-I
interacted with IPS-1 and EGCG added after signaling is initiated
is unlikely to inhibit the process. Furthermore, EGCG does not
inhibit IPS-1 or an event downstream of IPS-1 (Table 1). Taken
together all these results suggest that EGCG can bind to an RNA-
bound conformer of RIG-I and prevent signaling.
Structure Activity Relationship
To better understand how EGCG structure relates to its ability
to inhibit RIG-I, we tested several commercially available analogs,
including epicatechin gallate (ECG), epigallocatechin (EGC) and
the epimers gallocatechin gallate (GCG), catechin gallate (CG),
gallocatechin (GC), and theaflavin 3,39 digallate (TFDG) (Figure
S4). At 2 mM, EGCG, its epimer GCG, and the digallate TFDG
reduced RIG-I signaling by more than 60% (Figure 5A). TFDG
inhibited RIG-I signaling with IC50 value of approximately 1 mM
(data not shown). All the other analogs were less effective, reducing
RIG-I signaling by 20–40%. The analogs did not significantly
affect signaling by TLR3, TLR4, TLR9, or the constitutive
activities of IPS-1, R-C and R-CH (Figure 5A). However, at
10 mM all the EGCG analogs showed similar levels of inhibition of
RIG-I signaling but did not affect IPS-1 constitutive activity,
suggesting that the less effective inhibitors either had poorer
affinity for RIG-I or less optimal pharmacokinetic properties
(Figure 5A).
In the biochemical ATPase assay, GCG, ECG, CG and TFDG
inhibited the shR9-induced RIG-I ATPase activity to similar
degree as EGCG (Figure 5B). EGC and its epimer GC as well as
the control compound Clemizole did not show significant
inhibition at the two concentrations tested (Figure 5B). These
results show that analogs can bind recombinant RIG-I with similar
properties and that pharmacokinetic properties is the more likely
explanation for the differences in the results for the cell-based
assays.
Binding of EGCG to RIG-I
RIG-I can bind to select RNAs in a native gel electrophoresis
[7]. To further explore the potential RIG-I EGCG interaction we
analyzed the RIG-I-agonist complexes using an electrophoretic
mobility shift assay, followed by staining for the protein
(Figure 6A). RIG-I incubated with dsR27, but not with unpho-
sphorylated ssRNA, cssR27, exhibited a change in electrophoretic
mobility from the apoprotein. This suggests that the RIG-I
interacts with dsR27 but not with cssR27. A change in
electrophoretic property of RIG-I was also observed with shR9
and poly(I:C) of ,105 bps (Figure 6A). Interestingly, shR9 bound
RIG-I migrated as two distinct bands. This alternate mobility
could be due to the different conformations of the complex formed
between RIG-I and triphosphorylated RNA, shR9. These results
confirm that RIG-I interacts only with RNAs that are agonists for
signal transduction. Notably, ATP was not required for this
complex formation (Figure 6B).
The mobility shift assay was used to examine the effect of
EGCG on the RIG-I-dsR27 complex (Figure 6C). The addition of
EGCG, but not Clemizole, resulted in altered mobility of the RIG-
I-dsR27 complex. Along with the protein band with decreased
mobility, protein band with increased mobility (indicated by
asterisks in Fig. 6B) was also observed in the presence of EGCG
but not Clemizole. To determine whether dsR27 is associated with
RIG-I, the gel was stained with ethidium bromide (Figure 6D). A
corresponding decrease in protein and RNA was observed with
increasing amounts of EGCG but not with Clemizole. The RIG-I-
EGCG complex migrated with increased mobility but did not get
stained with ethidium bromide. No detectable RNase or protease
activity was observed when EGCG was added to RIG-I-RNA
complex (data not shown). These results suggests that the binding
of EGCG to RIG-I-RNA complex resulted in the release of RNA
agonist form the complex leading to a RIG-I-EGCG complex that
is inactive for signaling. A similar change was also observed with
TFDG (data not shown).
EGCG and IL6 production in BEAS-2B cells
Thus far, all of the cell-based effects of EGCG on RIG-I were
analyzed with RIG-I expressed by transient transfection and
Figure 2. EGCG does not compete with ATP binding of RIG-I. (A)
EGCG does not compete with ATP binding of RIG-I. Effect of ATP
concentration on EGCG inhibition of recombinant full length RIG-I
ATPase activity. Different amounts of ATP were added to the shR9
dependent ATPase activity in the presence of EGCG (1 mM) or DMSO. The
data are shown as a mean +/2 standard deviation. (B) Effect of EGCG on
ATPase activity deficient mutant K270A in cell-based reporter assay.
Signaling by WT and K270A mutant was analyzed using tripho-
sphorylated RNA shR9 and dsRNA mimic, poly(I:C) in the presence and
absence of EGCG (2 mM). K270A was incapableof signaling with shR9 but
could induce signaling with poly(I:C). Signaling of WT RIG-I with shR9 was
set as 100%. Assay was performed using IFN-b luciferase as reporter
plasmid and the data are shown as a mean +/2 standard deviation.
doi:10.1371/journal.pone.0012878.g002
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whether endogenously expressed RIG-I is susceptible to inhibition
by EGCG, we used a human bronchial epithelial cell line, BEAS-
2B. IL-6 production by BEAS-2B cells increased in response to
transfected triphosphorylated RNAs (shR9 and 3PcssR27), but not
to RNAs lacking a 59 triphosphate (cssR27) (Figure 7A).
Furthermore, shR9-induced IL6 production was significantly
decreased in the presence of siRNA against RIG-I but not with
the control nonspecific siRNA (NS), demonstrating that signaling
required RIG-I (Figure 7B). BEAS-2B cells can also induce IL-6
production upon activation with lipopolysaccharide (LPS) through
TLR4 [20]. RIG-I siRNA did not affect LPS-induced IL6
production (Figure 7B). To ensure that the effects of EGCG are
not as a result of cytotoxicity, we used a WST-1 assay to measure
the effects of EGCG on the cell viability of BEAS-2B cells. EGCG,
up to 8 mM did not show significant toxicity (Figure S5). These
results demonstrate that IL-6 production by BEAS-2B cells is
suitable for analysis of the effects of EGCG on endogenously
produced RIG-I.
EGCG inhibited shR9-induced IL6 production in BEAS-2B
cells in a concentration-dependent manner. EGCG also had only
minimal effects on LPS-induced IL-6 production (Figure 7C).
Some EGCG analogs also had inhibitory effects on shR9-induced
IL-6 production, with GCG, ECG, CG and TFDG inhibiting IL6
production better than did EGC and GC (Figure 7D top).
Clemizole, which did not affect RIG-I-dependent ATPase activity
and reporter activity in the HEK293T cells, did not inhibit shR9-
induced IL-6 production. No significant affect of LPS induced IL6
production was observed with any of the EGCG analogs
(Figure 7D bottom).
To confirm that the effects of EGCG are at the level of
transcriptional regulation in BEAS-2B cells, we analyzed the
production of IL6 mRNA by real-time PCR (Figure 7E). EGCG at
1 mM inhibited shR9-dependent IL6 mRNA synthesis by 80% but
did not significantly affect LPS-dependent IL6 mRNA synthesis.
Furthermore, EGCG inhibited shR9-dependent IFN-b mRNA
synthesis by 80% (Figure 7F). These results demonstrate that
EGCG modulated a RIG-I –dependent change in signal
transduction in a cell line with endogenous RIG-I pathway.
Discussion
The innate immune response provides the first line of defense
against invading pathogens. However, hyperactivity of these
receptors could lead to autoimmune disorders. In our attempt to
identify small molecule modulators of RIG-I we identified a green
tea polyphenol, EGCG, which could bind RIG-I and inhibit its
activation of signal transduction. EGCG did not interfere with
RNA or ATP binding by RIG-I and can affect the complex of
RIG-I and RNA (Figure 2, 3 and 6).
Interestingly, EGCG did not inhibit the constitutive signaling
activity of RIG-I (Figure 1A). The R-TS/A mutant showed
elevated ligand-independent signaling than WT RIG-I, but
retained response to ligand, suggesting that the mutations have
resulted in relaxed repression of CARD domain. Increasing
amounts of EGCG inhibited only the agonist-dependent signaling
but not the constitutive signaling by the TS/A mutant (Figure 4B).
Furthermore, EGCG did not inhibit the constitutive activities of
RIG-I deletion mutants R-C and R-CH (Figure 4A). These results
suggest that EGCG targets a conformer of the RIG-I complexed
with its agonist. Pre-treatment of cells with EGCG did not
augment inhibition of signaling or ATPase activity, suggesting that
EGCG did not prevent RNA ligand binding by RIG-I (Figure 2C–
E). However, the RNA signal normally present in complex with
RIG-I was decreased in the presence of EGCG, suggesting that
EGCG may be able to evict some RNAs in the RIG-I complex
Figure 3. RIG-I RNA binding is not affected by EGCG. (A–C). Cell based reporter assay to analyze the effect of EGCG (2 mM) on full length RIG-I
signaling with increasing concentrations of shR9 (A), blunt ended dsRNA, dsR27 (B) and poly(I:C) (C). Signaling observed with 10 nM of shR9, dsR27
and 0.2 mg/ml of poly(I:C) was considered as 100%. Assay was performed using IFN-b luciferase as reporter plasmid. All the data are shown as a mean
+/2 standard deviation. (D–F). Inhibition of full length RIG-I ATPase activity by EGCG was analyzed using different amounts of shR9 (D), dsR27 (E) and
poly(I:C) (F). ATPase activity obtained with 0.5 mM of shR9, dsR27, and 16 mg/ml poly(I:C) was normalized to 100%. All data are shown as a mean +/2
standard deviation.
doi:10.1371/journal.pone.0012878.g003
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ethidium bromide (Fig. 7D and data not shown). Finally, the cell-
based results are consistent with the biochemical results showing
that EGCG and some analogs can alter RNA-dependent ATPase
activity of RIG-I as well as the electrophoretic mobility of the
RIG-I-agonist complex (Figure 5 and 6).
In HEK293T cells over-experessing RIG-I and other related
innate immunity receptors, EGCG inhibited signaling by RIG-I
and MDA-5 but not by Toll like receptors 3, 4 and 9 (Table 1 and
Figure S2). In BEAS-2B cells expressing endogenous RIG-I and
TLR4, only the shR9-induced and not the LPS-induced IL-6
production was inhibited by EGCG and its analogs (Figure 7).
Finally, constitutive signal transduction by over-expressed IPS-1
was not affected by EGCG, indicating that EGCG does not act
downstream of the IPS-1 in this signaling pathway (Table 1). We
note that these experiments involve over-expression of IPS-1 and
hence is not intended to provide a physiological condition, only to
examine whether EGCG can suppress signaling downstream of
IPS-1.
Effects of EGCG on other targets
EGCG has been shown to interact with several proteins
including fibronectin, fibrinogen, laminin, laminin receptor,
glucose-regulated protein 78, ZAP-70 kinase etc [19,21–25].
EGCG was also reported to bind to T-cell receptor CD4 and
hence could have some potential for HIV therapy [26].
Reportedly EGCG inhibited TLR2 and TLR4 pathways in dental
pulp cells and gastric epithelial cells [27,28]. Furthermore, EGCG
has been reported to inhibit the activation of transcription factor,
NF-kB (possibly through the suppression of IkB kinase) and IRF3
(via suppression of kinase activity of TBK1) [29–32]. Our data are
in contrast with the latter reports, as we did not see any significant
inhibition of TLR3, TLR4, TLR9 and IPS-1 signaling measured
via NF-kB reporters in HEK293T cells over expressing these
receptors (Table 1). Furthermore, IL6 production in BEAS-2B
cells in response to LPS treatment was unaffected. The
discrepancy could be due to the amount of EGCG used in these
studies. The IC50 for both RIG-I dependent cell-based reporter
assays and ATPase assays was less than 2 mM of EGCG while the
other studies had used EGCG at more than 50 mM for significant
inhibition. We also observed that some EGCG analogs had
activities at 10 mM while EGCG and TFDG were effective at
,1 mM (Figure 5A). Thus it is possible that additional proteins will
be affected by higher EGCG concentrations.
Interpretation of SAR results
Analysis of EGCG agonists showed that EGCG and its epimer
GCG are the most potent inhibitors among the analogs tested
Figure 4. Mode of action of EGCG. (A) Constitutively active RIG-I mutants were not inhibited by EGCG. RIG-I deletion mutants expressing only the
dual CARD domains, R-C and CARD-helicase domains, R-CH was analyzed using the cell based reporter assay in the presence of EGCG (2 mM) or
DMSO. Black and white bars correspond to signaling activity observed in the absence and presence of transfected shR9. The data are shown as a
mean +/2 standard deviation. (B) EGCG inhibits only the agonist-dependent signaling of RIG-I. Cell based reporter assay was performed to determine
the effect of EGCG on WT RIG-I and mutant R-TS/A with (white bars) and without (black bars) transfected shR9. Amount of EGCG used is shown below
the x-axis. The data are shown as a mean +/2 standard deviation. (C) ATPase activity and order of addition of EGCG. EGCG was incubated with
recombinant full length RIG-I either together, 109 before or after shR9. ATP was then added to initiate ATPase activity. The data are shown as a mean
+/2 standard deviation. (D and E) RIG-I cell based assay and order of EGCG addition. EGCG was added together, 5 h before or after transfection of
shR9 into cells (D) or after every 1 h interval post transfection up to 5 h (E). EGCG failed to inhibit RIG-I signaling when added 1 h post transfection of
shR9. All assays were performed using IFN-b luciferase as reporter plasmid and the data are shown as a mean +/2 standard deviation.
doi:10.1371/journal.pone.0012878.g004
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requirement for the inhibition of ATPase activity and signaling.
EGCG, ECG and its epimers inhibited ATPase activity signifi-
cantly while EGC and GC did not (Figure 5). This suggests that
the cathechin gallate group participates in inhibition of ATPase
activity. To inhibit RIG-I signaling, the three adjacent hydroxyl
groups in the pyrogallol and galloyl group of the molecule appear
to be required. However, it is possible that the difference is due to
variations in the reaction conditions of the in vitro ATPase assay
and cell-based reporter assay.
Mechanism of EGCG inhibition
RIG-I can be activated by phosphorylated ssRNAs, dsRNAs as
well as non-phosphorylated dsRNAs [10,13,33]. Upon interaction
with RNA, RIG-I undergoes a conformational change leading to
dimerization of the RNA-bound protein (Figure 8). This complex
then interacts with adaptor protein, IPS-1, which is present on the
mitochondrion-associated membranes and peroxisomal mem-
branes leading to downstream signaling [34,35]. EGCG could
interfere with this pathway at number of positions (Figure 8). First,
EGCG could potentially bind to RIG-I and prevent its binding to
the RNA agonist. This would sequester RIG-I in a state that
cannot activate signal transduction. A second possibility is that
EGCG could bind to RNA bound form of RIG-I and induce a
different conformation resulting in the release of RNA. Third,
EGCG could prevent the ligand-induced dimerization. A fourth
possibility is that EGCG could bind to the RNA bound dimer of
RIG-I and inhibit it from interacting with its adaptor protein, IPS-
1. This complex may also be changed in the binding to the RNA
and/or conformation upon binding of EGCG and the fifth
possibility is that EGCG could interact with RIG-I-IPS-1 complex
and prevent down stream signaling.
The time of addition experiment suggested that EGCG could
inhibit RIG-I only after agonist binding and EGCG did not
compete with RNA binding (Figure 4C–E). This suggests that
EGCG did not prevent RNA binding thus ruling out scenario 1.
Since, EGCG did not inhibit constitutive signaling by RIG-I
mutants R-C, R-CH and R-TS/A (Figure 4A and 4B) it may not
interfere with interaction of RIG-I with IPS-1 (scenario 5). Since
EGCG does not compete with RNA binding (Figure 3), this could
be interpreted as EGCG can bind to a conformer induced upon
RIG-I-RNA interaction (scenario 2, 3 & 4). Native gel analysis
(Figure 6C and 6D) suggested that EGCG binding to RIG-I-
dsRNA complex resulted in the release of RNA from the complex
(scenario 2). RIG-I bound to RNA is throught to occur as a dimer
[3,13], thus the inhibition is likely at scenario 4. While these
studies provide several features for the interaction, additional
studies will be required to elucidate of the mechanism(s) through
which EGCG inhibits RIG-I signaling.
Biomedical implications
The identification of EGCG inhibition of RIG-I activity
provides proof of principle for small molecule modulators of this
target. RIG-I is involved in sensing viral infections, including
influenza virus and HCV [11,36]. While RIG-I plays an active
role in antiviral responses, these responses could also exacerbate
pathologies. We note that infection of Epstein Barr virus (EBV) has
been proposed to promote autoimmune diseases such as lupus
[37]. EBV encoded small RNAs are transcribed by RNA
polymerase III and are known to activate RIG-I [38]. In this
Figure 5. Structure activity relationship of EGCG. (A) Cell based reporter assay was used to test the effect of EGCG analogs (2 mM) on RIG-I,
TLR3, TLR4, TLR9, IPS-1, R-C, and R-CH. The effect of 10 mM of these compounds was tested on RIG-I and IPS-1. The numbers correspond to mean
percent activity in comparison to DMSO treated sample (taken as 100%). Standard deviation is given in parenthesis. TLR3, 4 & 9 assays used NF-kB-
luciferase as reporter plasmid and all others were performed with IFN-b luciferase as reporter plasmid. (B) Analysis of EGCG analogs on shR9
dependent RIG-I ATPase activity. Each compound was tested at 0.5 and 1 mM. Clemizole was used as a control compound. The data are shown as a
mean +/2 standard deviation.
doi:10.1371/journal.pone.0012878.g005
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engineering for both viral and autoimmune diseases. In addition,
the identification of EGCG or its derivatives could be used as tool
compounds to examine RIG-I signal transduction.
Materials and Methods
Constructs for expression in mammalian cells
The cDNA of RIG-I cloned in pUNO (pUNO-hRIG-I) was
from Invivogen. Constructs expressing the RIG-I CARD (R-C;
residues 1 to 229), and the CARD and helicase domains (R-CH; 1
to 734), were generated by amplifying the RIG-I cDNA sequence
corresponding residues with flanking Age I and Nhe I restriction
sites for cloning using these sites in the pUNO vector. All
constructs were checked by DNA sequencing using the BigDyeH
Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems,
USA).
Cell-based Reporter Assays
RIG-I assay was performed as per Ranjith-Kumar et al. [13]
with IFN-b luciferase as the reporter plasmid (a kind gift from Dr.
Rongtuan Lin, Lady Davis Institute for Medical Research,
Montreal, QC, Canada.), unless mentioned otherwise. shR9 was
transfected into the cells at 10 nM (final concentration). TLR3,
TLR4 and TLR9 assays were performed as previously described
[39] with pNiFty-Luc and the firefly reporter plasmid. Ligands for
TLR3, 4 were 9 were, respectively, poly(I:C) (500 ng/ml;
Amersham Biosciences), lipopolysaccharide (1 mg/ml; Sigma)
and ODN2006 (2 mM; Invivogen).
Library screens
Compounds were analyzed using the cell-based assay described
above. Compounds (dissolved in 10% DMSO) were added to the
media prior to transfection of shR9 agonist. The final concentra-
tion of DMSO in each well was 0.2%. The ratio of firefly to Renilla
luciferase values was calculated and the ratio obtained with agonist
was considered as 100%. Compounds that increased or decreased
signaling by 50% or more relative to DMSO controls are
designated as activators and inhibitors, respectively.
Expression and Purification of Recombinant RIG-I
RIG-I ORF was amplified and cloned into pET-28a vector at
the Nde I and Xho I sites. The recombinant clone was confirmed
by DNA sequencing and was transformed into Rosetta (DE3)
PhyS cells. The cells were induced with 0.2 mM of IPTG for 12–
16 h at 16uC and the RIG-I protein was first enriched using an Ni-
NTA column which was pre-equilibrated with 20 mM Tris,
pH 8.0, 300 mM NaCl, 10% glycerol, 10 mM imidazole, 5 mM
beta-mercaptoethanol and the protein was eluted with equilibra-
tion buffer containing 500 mM imidazole. Fractions containing
RIG-I were pooled, dialyzed against Buffer P containing 25 mM
Figure 6. Native PAGE analysis of RIG-I-EGCG interaction. (A) Recombinant RIG-I was incubated with different RNAs shown above the gel and
stained with Coomassie brilliant blue to detect RIG-I protein as indicated below the gel image. cssR27 is an unphosphorylated 27-mer ssRNA, dsR27 is
27-mer blunt ended dsRNA, shR9 triphosphorylated 60-mer short hairpin RNA and pIC105 is poly(I:C) of average length of 105 bp. A shift in RIG-I
mobility was observed only with RNAs that induced RIG-I signaling and ATPase activity. (B) Mobility shift does not require ATP. RIG-I was incubated
with or without dsR27 in the absence or presence of different amounts of ATP (given on top of the gel). The presence of dsR27 is denoted with + sign
above the gel. The gel is stained with Coomassie brilliant blue. (C) EGCG induces different mobility of RIG-I. Increasing concentrations of EGCG and
Clemizole were added to RIG-I-dsR27 complex. The presence dsR27 and identity of the compounds are given on the top of the gel. The gel is stained
with Coomassie blue and the fainter material with altered electrophoretic mobility is identified with white asterisks. (D) Same as (C) except the gel is
stained for RNA using ethidium bromide.
doi:10.1371/journal.pone.0012878.g006
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mercaptoethanol and purified by a Resource Q column (1 ml) that
was pre-equilibrated with Buffer P. The protein was eluted in a
buffer containing a gradient of 50 to 300 mM NaCl. Fractions
containing purified protein were collected and dialyzed against
buffer containing 25 mM Tris, pH 8.0, 175 mM NaCl, 10%
glycerol and 10 mM beta-mercaptoethanol and stored at 280uC
in aliquots.
ATPase Assay
ATPase assay used the ADP-Glo Kinase Assay kit using the
manufacturer’s guidelines (Promega Inc). The reaction was
performed in Buffer A: 20 mM Tris (pH 7.5), 5 mM MgCl2,
8 mM DTT, 30 mM NaCl and 4% glycerol that contained 1 mM
ATP, 1 mM RNA (unless specified otherwise), and 100 nM of
recombinant RIG-I protein unless stated otherwise. The samples
were processed using ADP-Glo and Kinase detection reagent and
luminescence was quantified using a Synergy 2 plate reader
(Biotek Inc.). EGCG did not interfere with the luminescence
detection.
Electrophoretic mobility shift assays
Recombinant RIG-I (0.8 mM) was mixed with 4 mM RNA agonist
and compounds (5–25 mM, DMSO was used for control), incubated
at 37uC for 15 minutes, followed by addition of native PAGE loading
buffer and separated on 10% PAGE at 4uC. The gel was then stained
with ethidium bromide and/or Coomassie brilliant blue.
WST-1 assay
To assess the effect of EGCG on cell viability of HEK293T and
BEAS2B cells (ATCC), an in vitro colorimetric assay (WST-1 assay,
Clontech, Mountain View, CA) was used. Cells were treated with 0–
8 mM of EGCG (triplicates per dose). After 18 h, 10 mlo fW S T - 1
reagent/100 mlmedium was added to eachwell.After 1–6 h at 37uC,
absorption was measured at 450 nm with 630 nm as reference using
a microplate reader and corrected to blank values (wellswithout cells).
Figure 7. Effect of EGCG in BEAS-2B cells. (A) IL6 secretion by BEAS-2B cells was analyzed after transfection with different RNAs. Mock
corresponds to no RNA transfected, cssR27 is an unphosphorylated 27-mer ssRNA, 3PcssR27 is same as cssR27 but with 59 triphosphates and shR9
triphosphorylated 60-nt short hairpin RNA. The data are shown as a mean +/2 standard deviation. (B) IL6 production induced by transfection of shR9
is via recognition by RIG-I. BEAS-2B cells were mock transfected or transfected with siRNA to RIG-I or control siRNA (NS). These cells were either
transfected with shR9 or treated with LPS to induce secretion of IL6. The data are shown as a mean +/2 standard deviation. (C) EGCG inhibits shR9
dependent IL6 production but LPS dependent IL6 production is unaffected. IL6 secretion in the absence of EGCG is normalized to 100%. The
concentration of EGCG used is shown below the x-axis. The data are shown as a mean +/2 standard deviation. (D) EGCG analogs and IL6 production.
Effect of EGCG analogs on IL6 production by transfected shR9 (top) and added LPS (bottom) was analyzed. The analogs used are given at the bottom
of the graph. Clemizole was used as the control. The data are shown as a mean +/2 standard deviation. (E) Real time PCR analysis to determine the
mRNA levels of IL6. Fold activation of IL6 mRNA was determined using quantitative RT-PCR. Data were normalized to the gylceraldehyde-3-phosphate
dehydrogenase levels in each sample and reported as fold induction of non-stimulated control cells. The data are shown as a mean +/2 standard
deviation. (F) EGCG inhibited IFN-b mRNA accumulation. IFN-b was analyzed in the presence and absence of EGCG in shR9 or mock transfected BEAS-
2B cells and represented as given in (E). The data are shown as a mean +/2 standard deviation.
doi:10.1371/journal.pone.0012878.g007
EGCG Modulates RIG-I Signaling
PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12878Measurement of IL6 level in culture supernatant
Supernatants from BEAS2B cells were collected 24 h after
treatments and stored at 220uC or assayed immediately for IL6
secretion using a human IL6 ELISA kit (R&D systems) as per
manufacturer’s protocol.
RT-PCR
Total RNA was isolated from BEAS2B cells using the RNeasy
Kit (QIAGEN, Valencia, CA) and digested with RNase-free
DNase I (QIAGEN). RNA (0.5 mg) was then reversed transcribed
to cDNA using Superscript III reverse transcriptase (Invitrogen,
Carlsbad, CA) and random primers (New England Biolabs). Real-
time PCR was performed using the Mastercycler ep realplex
(Eppendorf). PCR amplications were performed in a total volume
of 20 ml, containing 0.6 ml of cDNA and 200 nM of each primer,
using SYBR Green I PCR reagents (Applied Biosystems). Data
were normalized with gylceraldehyde-3-phosphate dehydrogenase
levels in each sample and reported as fold induction of non-
stimulated control cells. Primer sets: IL6 (sense, 59CACAGA-
CAGCCACTCACCTC-39; anti-sense, 59 AGCTCTGGCTTG-
TTCCTCAC-39 IFN-b (sense, 59-TGCTCTCCTGTTGTGC-
TTCTCC-39; anti-sense, 59-CATCTCATAGATGGTCAATG-
CGG-39. GAPDH (sense, 59-GAGTCAACGGATTTGGTCGT-
39; anti-sense, 59-TGGGATTTCCATTGATGACA-
Supporting Information
Figure S1 (A) Representative figure showing the cell based assay
results of screening of certain compounds. The assay was
performed using IFN-b luciferase as reporter. Asterisk depicts
result obtained with EGCG. The data are shown as a mean +/2
standard deviation. (B) Representative ATPase assay used for
confirming cell based reporter assay result. Asterisk depicts result
obtained with EGCG. 2006 corresponds to ODN2006, which was
earlier shown to be a RIG-I inhibitor (Ranjith-Kumar et al., 2009).
The data are shown as a mean +/2 standard deviation. (C) Effect
of RIG-I protein concentration on EGCG inhibition of shR9
dependent ATPase activity. The amount of RIG-I protein used is
shown below the graph. Black and white bars correspond to
DMSO and EGCG (1 mM) treatment respectively. ATPase
activity observed with 100 nM RIG-I treated with DMSO was
taken as 100%. The data are shown as a mean +/2 standard
deviation.
Found at: doi:10.1371/journal.pone.0012878.s001 (0.05 MB
PDF)
Figure S2 Effect of EGCG on MDA5 signaling. EGCG
inhibited poly(I:C) dependent MDA5 signaling in HEK293T cells
with IFN-b luciferase as reporter. MDA5 signaling in the absence
of EGCG was taken as 100%. The data are shown as a mean +/2
standard deviation.
Found at: doi:10.1371/journal.pone.0012878.s002 (0.03 MB
PDF)
Figure S3 Cell based reporter assay using RIG-I RNA-binding
mutants. RIG-I and mutant expressing HEK293T cells were mock
transfected or transfected with shR9 in the presence of 2 mMo f
EGCG or DMSO. Assay was performed using IFN-b luciferase as
reporter plasmid. Signaling activity observed with shR9 transfect-
ed WT RIG-I treated with DMSO was considered as 100%. The
data are shown as a mean +/2 standard deviation.
Found at: doi:10.1371/journal.pone.0012878.s003 (0.03 MB
PDF)
Figure 8. A model depicting RIG-I activation of signal transduction and the potential site of action of EGCG. Different domains of RIG-I
depicted are, CARD (N-terminal dual CARD domains), Hel (helicase domain), RD (C-terminal Regulatory domain). Different numbers correspond to
potential site of action of EGCG. IPS-1 is the adapter of RIG-I and is localized on the mitochondrial membrane (depicted as double line). More details
can be found in the text.
doi:10.1371/journal.pone.0012878.g008
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analog is given under the structure.
Found at: doi:10.1371/journal.pone.0012878.s004 (0.05 MB
PDF)
Figure S5 Analysis of cytotoxicity of EGCG in BEAS-2B cells.
WST-1 assay was used to determine the toxicity of EGCG in
BEAS-2B cells. The amounts of EGCG added to the cells are
given below the graph. The data are shown as a mean +/2
standard deviation.
Found at: doi:10.1371/journal.pone.0012878.s005 (0.03 MB
PDF)
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